Charles River Laboratories International, Inc. (CRL), a prominent provider of drug discovery, non-clinical development, and safety testing services, is set to report its fiscal third-quarter earnings for 2025 before the market opens on Wednesday, November 5th. The company, headquartered in Wilmington, Massachusetts, plays a crucial role in supporting pharmaceutical, biotechnology, government, and academic institutions as they accelerate research and the development of new medications. Current market expectations suggest a reported profit of $2.32 per share, representing a 10.4% decrease from the $2.59 per share recorded in the previous year’s third quarter. This projection comes amidst a backdrop of consistent performance, with CRL having exceeded Wall Street’s bottom-line estimates in each of the last four quarters, most recently posting earnings of $3.12 per share in the preceding quarter, a notable 24.8% above the consensus estimates.
The anticipation surrounding CRL’s upcoming earnings report is bolstered by optimistic analyst assessments. Throughout the company’s recent history, particularly highlighted by the solid Q2 results, a “Moderate Buy” rating has been consistently assigned by Wall Street. Currently, sixteen analysts actively cover CRL, with eight recommending a “Strong Buy” and eight maintaining a “Hold” rating. The collective sentiment is underpinned by a mean price target of $187.15 per share, hinting at a potential upside from the company’s current trading levels. This suggests that although there’s cautious optimism, the majority view is that CRL’s stock has significant room for growth.
A key factor influencing this positive outlook is CRL’s performance in the most recent quarter. On August 6th, the company’s stock experienced a significant drop of 10.3% following the release of its Q2 earnings data. Despite achieving better-than-expected revenue of $1 billion and an adjusted earnings per share (EPS) of $3.12, which significantly surpassed consensus estimates, the stock reacted negatively. This downturn was largely attributed to concerns surrounding a slowdown in the company’s Discovery and Safety Assessment (DSA) segment, a critical component of CRL’s business. Further investigation revealed that while top-line revenue increased marginally compared to the year-ago period, the bottom-line growth experienced a 11.4% surge, driven primarily by favorable foreign currency movements.
However, CRL responded to these investor anxieties by raising its fiscal 2025 guidance. The company now projects an adjusted EPS range of $9.90 to $10.30, and a modest revenue decline of 0.5% to 2.5%. This revised outlook, coupled with continued expectations of a recovery in the DSA segment—a potentially pivotal moment for the company’s overall trajectory—has reaffirmed analyst confidence and contributed to the stock’s positive momentum. CRL’s performance has also demonstrated resilience relative to broader market trends. While the S&P 500 Index ($SPX) has seen a 14.5% uptick over the past 52 weeks, CRL’s shares have lagged slightly, rising by a marginal 0.9% during the same period. More significantly, the company has outperformed the Health Care Select Sector SPDR Fund (XLV), which has dropped 3.4% over the same timeframe. These achievements place CRL favorably against its industry counterparts, and further strengthen the argument for a potential upside in its share price.
Neharika Jain did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
